Present invention relates to anti-CD33 antibodies, specifically related to human CD33 epitomes, which are inside of amino acid sequences FFHPIPYYDKNSPVHGYW (SEQ ID NO : 141), and application therefor immunotherapies based on myeloid cell depletion; particularly, for the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).